Business Context and Reporting Period
Company: DiaMedica Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 31, 2019
Event: The Company completed a "Continuance," moving its corporate existence from the Canada Business Corporations Act (CBCA) to the British Columbia Business Corporations Act (BCBCA). This action was approved by shareholders on May 22, 2019.
Financial Metrics
This filing is a current report regarding a corporate governance change and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing explicitly states that the Continuance did not result in any change to the Company's assets, liabilities, or net worth.
Material Changes Versus Prior Period
The primary material change is the shift in the governing legal jurisdiction from federal Canadian law (CBCA) to provincial British Columbia law (BCBCA). Key operational impacts include:
- Legal Entity Status: The Company remains the same legal entity for all purposes, retaining all rights, properties, debts, and obligations.
- Shareholder Rights: Outstanding shares, options, warrants, and employee benefit plans continue unchanged in terms and conditions.
- Management and Operations: No changes to headquarters, business operations, jobs, management, office locations, or employee count.
- Contractual Obligations: No impact on material contracts with third parties.
Guidance, Outlook, and Governance Changes
Management Commentary: Management notes that while shareholder rights under the BCBCA are substantively similar to the CBCA, there are notable differences in corporate governance mechanics.
Key Governance Differences (CBCA vs. BCBCA):
- Director Residency: BCBCA removes the requirement for 25% of directors to be resident Canadians.
- Director Removal: BCBCA requires a special resolution to remove a director; CBCA allowed removal by ordinary resolution.
- Shareholder Proposals: BCBCA requires a two-year holding period for shareholders to submit proposals (vs. six months under CBCA).
- Special Meetings: BCBCA allows up to four months to hold a special meeting upon 5% shareholder demand (vs. 21 days under CBCA).
- Oppression Claims: BCBCA allows court relief for threatened prejudicial effects and requires court leave for non-shareholders to bring claims.
- Amendments: BCBCA permits amendments to Articles via ordinary resolution and allows the Board to approve share subdivisions/consolidations without shareholder approval.
Indemnification: The Company entered into new Indemnification Agreements with directors and officers to align with BCBCA requirements, maintaining similar coverage for expenses and liabilities incurred in good faith.
Investor Verification Checklist
- Verify the specific terms of the new "Notice of Articles" and "Articles" filed as Exhibits 3.1 and 3.2.
- Review the 2019 Proxy Statement (filed April 8, 2019) for the full description of "Voting Proposal Three" regarding the Continuance.
- Confirm that existing options and warrants retain their original exercise prices and vesting schedules post-Continuance.
- Assess the impact of the extended timeline for special shareholder meetings (up to 4 months) on shareholder activism.